Ligand ID: 2DI Drugbank ID: DB00900(Didanosine) Indication:For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection in adults. |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 1z1j | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 10 | GLY B1029VAL B1018GLY B1120VAL B1036HIS B1041 | 1.38A | 23.60 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 2d2d | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 10 | GLY B 29VAL B 18GLY B 120VAL B 36HIS B 41 | 1.26A | 22.52 | NoneNoneNoneNoneENB B1145 (-3.4A) | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 2fav | REPLICASEPOLYPROTEIN 1AB(PP1AB) (ORF1AB) (SARSr-CoV) | 5 / 10 | GLY A 80VAL A 96GLY A 98THR A 77HIS A 43 | 1.78A | 20.76 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 3d62 | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 10 | GLY A 29VAL A 18GLY A 120VAL A 36HIS A 41 | 1.40A | 22.52 | NoneNoneNoneNone959 A 350 (-3.9A) | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 3e91 | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 10 | GLY A 29VAL A 18GLY A 120VAL A 36HIS A 41 | 1.38A | 22.82 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 3i6l | HLA, A-24NUCLEOPROTEINPEPTIDE (Homosapiens;SARSr-CoV) | 5 / 10 | PHE F 2GLU D 63GLY D 65VAL D 34HIS D 70 | 1.64A | 3.09 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 3iwm | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 10 | GLY A 29VAL A 18GLY A 120VAL A 36HIS A 41 | 1.31A | 22.82 | NoneNoneNoneNonePJE H 5 (-4.9A) | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 3m3t | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 10 | GLY A 11PHE A 150GLY A 15MET A 17VAL A 157 | 1.80A | 23.03 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 3m3v | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 10 | GLY A 29VAL A 18GLY A 120VAL A 36HIS A 41 | 1.29A | 22.96 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 5c8s | GUANINE-N7METHYLTRANSFERASE (SARSr-CoV) | 5 / 10 | GLY B 110GLY B 88ASN B 116VAL B 115HIS B 268 | 1.53A | 19.89 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 5x58 | SPIKE GLYCOPROTEIN (SARS-COVBJ01) | 5 / 10 | GLY C 638PHE C 629VAL C 596ASN C 627HIS C 641 | 1.76A | 12.79 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 6acd | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 10 | PHE B 22GLY B 246ASN B 135VAL B 25HIS B 149 | 1.71A | 12.45 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 6cs1 | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 10 | PHE A1044VAL A 711MET A 709THR A1009VAL A 763 | 1.80A | 11.97 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 6m0j | ACE2 (Homosapiens) | 5 / 10 | GLY A 130GLU A 171VAL A 172THR A 129VAL A 132 | 1.60A | 19.93 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 6m17 | ACE2 (Homosapiens) | 5 / 10 | GLY D 756VAL D 754GLY D 751MET D 750VAL D 758 | 1.79A | 17.57 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 5 / 10 | VAL A 675THR A 324ASN B 118VAL A 398HIS A 347 | 1.80A | 15.65 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 10 | PHE A 859VAL A 848GLY A 852ASN A 416VAL A 844 | 1.36A | 15.65 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 10 | GLY A 345VAL A 354THR A 344ASN A 356VAL A 535 | 1.57A | 15.65 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 6nur | NSP12 (SARSr-CoV) | 5 / 10 | GLY A 345VAL A 354THR A 344ASN A 356VAL A 535 | 1.51A | 16.16 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 6wen | NSP3 (SARS-CoV-2) | 5 / 10 | GLY A 78GLU A 104VAL A 77GLY A 97HIS A 138 | 1.78A | 22.26 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 10 | GLY A 78GLU A 104VAL A 77GLY A 97HIS A 138 | 1.79A | 21.40 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 6 / 10 | PHE D 156VAL D 49GLY D 48ASN C 58VAL D 24HIS C 86 | 1.70A | 22.11 | EDO D 209 ( 3.6A)EDO D 209 (-4.6A)EDO D 209 ( 4.7A)EDO D 209 (-4.6A)NoneNone | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 6 / 10 | PHE D 156VAL D 49GLY D 48ASN C 58VAL D 24HIS C 86 | 1.63A | 22.11 | EDO D 204 (-3.9A)APR D 201 (-3.7A)EDO D 204 ( 3.4A)EDO D 204 (-3.8A)NoneNone | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 10 | PHE D 156GLY D 47ASN C 58VAL D 24HIS C 86 | 1.77A | 22.11 | EDO D 204 (-3.9A)APR D 201 ( 4.3A)EDO D 204 (-3.8A)NoneNone | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 7btf | NSP12 (SARS-CoV-2) | 5 / 10 | GLY A 345VAL A 354THR A 344ASN A 356VAL A 535 | 1.54A | 15.65 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 7btf | NSP12NSP8 (SARS-CoV-2) | 5 / 10 | VAL A 675THR A 324ASN B 118VAL A 398HIS A 347 | 1.71A | 15.65 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 10 | GLY A 345VAL A 354THR A 344ASN A 356VAL A 535 | 1.55A | 15.63 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 5 / 10 | VAL A 675THR A 324ASN B 118VAL A 398HIS A 347 | 1.78A | 15.63 | None | ||
![]() | 1V3Q_E_2DIE290_1 (PURINE NUCLEOSIDEPHOSPHORYLASE) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 10 | GLY A 345VAL A 354THR A 344ASN A 356VAL A 535 | 1.55A | 15.63 | None |